I. MODIFIED AGREEMENTS

Company* (Country; Symbol)

Company* (Country; Symbol)

Product

Terms/Details (Date)

Maxygen Inc. (MAXY)

Codexis Inc.*

Codexis got additional rights to Maxygen's Molecular Breeding directed evolution platform

Codexis, a spin-off of Maxygen, got rights for certain applications relating to energy, including biofuels; Maxygen would receive an undisclosed percentage of resulting revenues (12/5)

Maxygen Inc. (MAXY)

Amgen Inc. (AMGN)

Maxygen is getting $17.8M in cash in exchange for its equity interest in Avidia Inc., which was acquired by Amgen

It also could get another $2.8M in the deal; Maxygen retains exclusive rights to use Avidia technology to develop products directed to more than 10 targets (10/29)

Micromet Inc. (MITI)

Serono SA (Switzerland; NYSE:SRA)

They amended deal covering development of the cancer drug adecatumumab (MT201)

Micromet's option to co-promote the product was extended one year; Micromet will continue running early trials, which are being funded by Serono (12/5)

Targeted Genetics Corp. (TGEN)

Biogen Idec Inc. (BIIB)

Biogen is converting $5.65M of Targeted Genetics debt into 1M Targeted Genetics shares under an amended agreement

Another $0.5M of debt will be paid immediately, and the remaing $2M will be repaid according to a new schedule; Biogen's stake in Targeted Genetics increased to 19.9 (11/7)

II. TERMINATED AGREEMENTS

Company* (Country; Symbol)

Company* (Country; Symbol)

Product

Terms/Details (Date)

Adolor Corp. (ADLR)

EpiCept Corp. (EPCT)

Adolor no longer will pursue development of a sterile lidocaine patch for post-surgical incisional pain

Adolor licensed North American rights to the product in 2003; EpiCept now has worldwide rights to the product, which was in Phase II development (10/31)

Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

NYSE = New York Stock Exchange.